Sequana Medical
Update in progressSEQUA.BR (Brussels)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Sequana Medical NV develops and commercializes treatments for diuretic-resistant fluid overload in liver disease, cancer, and heart failure. Based in Ghent, Belgium, the company operates in Belgium, Germany, France, and internationally. It offers the alfapump system, an implanted pump for refractory liver ascites and malignant ascites, and Direct Sodium Removal (DSR) for systemic fluid overload. Founded in 2006.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.56
- Governance
- 0.20
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.21
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.36
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!